FindTrial
Sign In

effect of shalaparni churna in the prevention of ageing in pregeriatric people

EFFECT OF SHALAPARNI CHURNA ON TELOMERE LENGTH IN HUMAN BLOOD MONONUCLEAR CELLS â?? AN EXPLORATORY OPEN CLINICAL TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028772
Enrollment
10
Registered
2020-10-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Shalaparni churna: Shalaparni churna with milk as anupana 6gm BD with 60 days Control Intervention1: Not Applicable: Not Applicable

Sponsors

Dr Latika Kaushik
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects aged between 50-60 years. 2. Either gender, irrespective of religion, occupation, economic status. 3. Those with proper vitals (temperature, heart rate, pulse, BP, respiratoty rate etc) 4. Willing to give consent for participating in the study.

Exclusion criteria

Exclusion criteria: 1. Patient below 50 years and above 60 years. 2. History of Severe Systemic illness like Peptic ulcer, Inflammatory Bowel Diseases, DM, HIV I & II, HTN & Pregnancy. 3. Known case of Crohnâ??s Disease, Ulcerative Colitis, and Malignancy & Tuberculosis. 4. Patients with other major systematic disorders which interfere with the treatment will be excluded.

Design outcomes

Primary

MeasureTime frame
Study provides pre clinical scientific evidence for Vayasthapan drugsTimepoint: 60 days—

Secondary

MeasureTime frame
Study provides pre clinical scientific evidence for Vayasthapan drugsTimepoint: 18 months—

Countries

India

Contacts

Public ContactDr kashavva v hiremath

KAHERS shri BMK ayurveda mahavidyalaya shahapur belgaum

kvhiremath.kaher@kleayurworld.edu.in9448945687

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026